STORM Therapeutics Limited Revenue
Biotechnology Research • 
Cambridge, England, United Kingdom • 21-50 Employees
STORM Therapeutics Limited revenue & valuation
| Annual revenue | $2,300,000 |
| Revenue per employee | $66,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $7,400,000 |
| Total funding | $30,000,000 |
Key Contacts at STORM Therapeutics Limited
Sapna Mistry
Executive Director, Program Team Lead
Helen Harrison
Director Of Discovery Biology
Byron Andrews
Director, Biology
Elizabeth Anderson
Director Of Pharmacology And Cancer Drug Discovery
Yaara Ofir-Rosenfeld
Director, Translational Oncology
Company overview
| Headquarters | Babraham Research Campus, Moneta Building, Cambridge, CB22 3AT, GB |
| Phone number | +441223804174 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Oncology, Drug Discovery, Biotech, Mass Spectrometry, Epigenetics, Rna Modifications |
| Founded | 2015 |
| Employees | 21-50 |
| Socials |
STORM Therapeutics Limited Email Formats
STORM Therapeutics Limited uses 3 email formats. The most common is {first name}.{last name} (e.g., john.doe@stormtherapeutics.com), used 56.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@stormtherapeutics.com | 56.5% |
{first initial}.{last name} | j.doe@stormtherapeutics.com | 34.8% |
{first name} | john@stormtherapeutics.com | 8.7% |
About STORM Therapeutics Limited
STORM Therapeutics is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets. STORM has leveraged its first mover advantage to establish a novel drug discovery and RNA analytics platform leading to the identification of novel targets and a proprietary pipeline of first in class small-molecule drug candidates for potential use in oncology, inflammation, viral infections, and CNS diseases. The pipeline is exemplified by STORM’s METTL3 inhibitor (STC-15) for which an IND has been filed with the FDA to support initiation of a Phase I clinical trial in cancer patients in 2022. STC-15 represents the first RNA modifying enzyme inhibitor to enter clinical evaluation in humans. Additional candidates are planned for advancement into IND-track activities in 2023. STORM has built an experienced R&D team who occupy modern, well-equipped laboratories on the Babraham Research Campus near Cambridge, UK. The company’s proprietary in house research is complemented by outsourcing of some discovery activities to high quality CRO partners (e.g., Evotec) enabling STORM to operate a cost efficient and flexible model.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
STORM Therapeutics Limited has 10 employees across 6 departments.
Departments
Number of employees
Funding Data
Explore STORM Therapeutics Limited's funding history, including investment rounds, total capital raised, and key backers.
STORM Therapeutics Limited Tech Stack
Discover the technologies and tools that power STORM Therapeutics Limited's digital infrastructure, from frameworks to analytics platforms.
Web servers
Security
JavaScript libraries
Tag managers
Hosting
CMS
Programming languages
Font scripts
Miscellaneous
Analytics
Pakistan
Philippines
South Africa
Frequently asked questions
4.8
40,000 users
